The treatment of envenomation with effective snake antivenom immunoglobins has become a critical worldwide health issue. Current methods for testing the effectiveness of new antivenom mixtures in neutralizing venom toxicity/lethality use animal models (e.g. mice). Neutralization of venom toxicity/lethality requires the formation of venom-antivenom immune complexes (though the extent of complex formation in vivo is unknown). Size-exclusion high-performance liquid chromatography (SE-HPLC) is a reproducible quantitative method to characterize venom-antivenom immune complex formation in vitro within a relatively short time. Changes in SE-HPLC elution profiles due to dose-dependent formation of venom-antivenom immune complexes are present for 1) Crotalis atrox (western diamondback rattlesnake) venom and the current antivenom used clinically in North America [FabAV (Ovine); CroFab™], and 2) Bothrops jararaca venom (Brazil) and Bothropic antivenom [F(ab')2AV (Equine); Brazil]. Changes in profile region areas were fit to a hyperbolic dose-response function to estimate maximum binding and venom/antivenom concentrations at half-maximum binding.
|Original language||American English|
|State||Published - 22 Aug 2020|
|Event||Oklahoma State University Center for Health Sciences Research Day 2019 - Oklahoma State University Center for Health Sciences, TULSA, United States|
Duration: 21 Feb 2019 → 22 Feb 2019
|Conference||Oklahoma State University Center for Health Sciences Research Day 2019|
|Abbreviated title||Research Day 2019|
|Period||21/02/19 → 22/02/19|